DDrare: Database of Drug Development for Rare Diseases

274. 骨形成不全症
［臨床試験数：78，薬物数：87（DrugBank：19），標的遺伝子数：14，標的パスウェイ数：74］

Searched query = "Osteogenesis Imperfecta"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACLASTA; AMG 162; AMG 785; ANTI-SCLEROSTIN MONOCLONAL ANTIBODY; Aclasta; Actonel 5mg Film Coated Tablets; Actonel Once a Week 35 mg film-coated tablets; Actonel/Optinate 5mg film-coated tablets; Alendronate; Alendronic acid; Anti-sclerostin monoclonal antibody; BOOST cells; BPS804; Bisphosphonates; Blood sample; Bone marrow transplant; Bonefos; Busulfan; Calcichew tablets; Calcium; Celulas madre mesenquimales troncales adultas alogenicas de médula ósea no expandida; Cyclophosphamide; Cyclosporin; Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas; Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada PEI nº 12-088); DENOSUMAB; Denosumab; Denosumab - - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand; Denosumab - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand; Denusomab; Disodium Pamidronate 15mg (15mg strength); Expanded human first trimester fetal liver-derived mesenchymal stem cells; Forsteo; Fresolimumab; GENOTROPIN*1TBF 5,3MG (16UI); H05AA02; High-dose vitamin D (2000 IU per day); Humatrope; Ibandronic acid; Ibandronic acid solution; Mesenchymal Stem Cells; Mesenchymal Stromal Cells; NERIXIA*INFUS IV CONC 2F 100MG; Optinate 5 mg filmcoated tablets; Other: Bone Marrow Cell Transplantation; Other: No active treatment; Other: saline; Pamidronate; Pamidronate (Aredia); Pamidronate sodium; Procedure: Mesenchymal Stem Cell Transplantation; Prolia; REF CRUZADA PEI Nº 12-088; RITUXIMAB; ROMOSOZUMAB; Radiation: Irradiation, Total Body; Risedronate; Risedronate Oral Tablet; Risedronate Sodium; Risedronate sodium; Risedronate sodium (Actonel); Risedronate sodium 2.5mg; Risedronate sodium 5mg; Risedronato sódico 2.5mg; Risedronato sódico 5mg; Risedronic acid; Rituximab; Romosozumab; Setrusumab; Somatropin; Standard-dose vitamin D (400IU per day); Teriparatide; Teriparatide (FORTEO); Teriparatide Pen Injector; VARI; Vitamin D; XGEVA; Xgeva; ZOL446; ZOLEDRONIC ACID; Zoledronic Acid; Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product; Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product.; Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion,generic medicinal product; Zoledronic acid; Zometa; Ácido risedrónico

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-005096-27-DK (EUCTR)	23/06/2017	24/03/2017	A study of test product setrusumab in adults with brittle bone syndrome.	A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, incorporating an open label substudy, in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with setrusumab (BPS804).	Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: setrusumab Product Code: BPS804 INN or Proposed INN: setrusumab Other descriptive name: ANTI-SCLEROSTIN MONOCLONAL ANTIBODY Trade Name: Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion,generic medicinal product Product Name: Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product. INN or Proposed INN: ZOLEDRONIC ACID	Mereo BioPharma 3 Ltd.	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 2	United States;France;Canada;Denmark;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2016-005096-27-DK
(EUCTR)

23/06/2017

24/03/2017

A study of test product setrusumab in adults with brittle bone syndrome.

A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, incorporating an open label substudy, in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with setrusumab (BPS804).

Osteogenesis imperfecta
MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]

Product Name: setrusumab
Product Code: BPS804
INN or Proposed INN: setrusumab
Other descriptive name: ANTI-SCLEROSTIN MONOCLONAL ANTIBODY
Trade Name: Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion,generic medicinal product
Product Name: Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product.
INN or Proposed INN: ZOLEDRONIC ACID

Mereo BioPharma 3 Ltd.

NULL

Not Recruiting

Female: yes
Male: yes

100

Phase 2

United States;France;Canada;Denmark;United Kingdom